SEI Investments
FDMT icon

SEI Investments’s 4D Molecular Therapeutics FDMT Stock Holding History

SEI Investments’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$120K Buy
12,862
+1,050
+9% +$9.14K ﹤0.01% 3068
2025
Q4 		$88.6K Buy
11,812
+139
+1% +$1.41K ﹤0.01% 3028
2025
Q3 		$101K Sell
11,673
-16,862
-59% -$101K ﹤0.01% 2714
2025
Q2 		$106K Buy
28,535
+103
+0.4% +$362 ﹤0.01% 2682
2025
Q1 		$91.8K Buy
+28,432
New +$134K ﹤0.01% 2612
2024
Q2 		– Sell
-15,818
Closed -$504K – 2673
2024
Q1 		$504K Buy
+15,818
New +$404K ﹤0.01% 2113

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SEI Investments's FDMT Position: Q1 2026 in Review

SEI Investments increased its 4D Molecular Therapeutics (FDMT) stake by 8.9% in Q1 2026, buying an estimated $9.14K and bringing the position to 12,862 shares worth $120K. The position accounts for ﹤0.01% of the portfolio, ranked #3068.

SEI Investments first reported a position in FDMT in Q1 2024 and has held it in 6 quarters since. The position peaked at $504K in Q1 2024. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • SEI Investments held 12,862 shares of 4D Molecular Therapeutics worth $120K as of Q1 2026.
  • SEI Investments bought 1,050 4D Molecular Therapeutics shares in Q1 2026, an estimated $9.14K.
  • 4D Molecular Therapeutics made up ﹤0.01% of SEI Investments's portfolio in Q1 2026, its #3068 holding.
  • SEI Investments first reported a position in 4D Molecular Therapeutics in Q1 2024 and has held it in 6 quarters since.
  • SEI Investments's 4D Molecular Therapeutics position peaked at $504K in Q1 2024.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on SEI Investments's 13F filing for Q1 2026, filed 13 May 2026.